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INTRODUCTION: Renal artery stenosis can lead to renovascular hypertension; however, the detection of stenosis alone does not 
guarantee the presence of renovascular hypertension. Renovascular hypertension depends on activation of the renin-angiotensin 
system, which can be detected by functional tests such as captopril renal scintigraphy. A method that allows direct measurement of 
the baseline and post-captopril glomerular filtration rate using chromium-51 labeled ethylenediamine tetraacetic acid (51Cr-EDTA) 
could add valuable information to the investigation of hypertensive patients with renal artery stenosis. The purposes of this study 
were to create a protocol to measure the baseline and post-captopril glomerular filtration rate using 51Cr-EDTA, and to verify whether 
changes in the glomerular filtration rate permit differentiation between hypertensive patients with and without renal artery stenosis. 
METHODS: This prospective study included 41 consecutive patients with poorly controlled severe hypertension. All patients had 
undergone a radiological investigation of renal artery stenosis within the month prior to their inclusion. The patients were divided 
into two groups: patients with (n=21) and without renal artery stenosis, (n=20). In vitro glomerular filtration rate analysis (51Cr-
EDTA) and 99mTc-DMSA scintigraphy were performed before and after captopril administration in all patients. 
RESULTS: The mean baseline glomerular filtration rate was 48.6±21.8 ml/kg/1.73 m2 in the group wuth renal artery stenosis, 
which was significantly lower than the GFR of 65.1±28.7 ml/kg/1.73m2 in the group without renal artery stenosis (p=0.04). Cap-
topril induced a significant reduction of the glomerular filtration rate in the group with renal artery stenosis (to 32.6±14.8 ml/
kg/1.73m2, p=0.001) and an insignificant change in the group without RAS (to 62.2±23.6 ml/kg/1.73m2, p=0.68). Scintigraphy 
with technetium-99m dimercapto-succinic acid (DMSA) did not show significant differences in differential renal function from 
baseline to post-captopril images in either group. 
CONCLUSIONS: Captopril induced a decrease in the GFR that could be quantitatively measured with 51Cr-EDTA. The reduction 
is more pronounced in hypertensive patients with RAS.
KEYWORDS: Renal Artery Obstruction; Renovascular Hypertension; Glomerular Filtration Rate; Chromium EDTA; Angiotensin-
Converting Enzyme Inhibitors.
INTRODUCTION
Renovascular hypertension (RVH) is a potentially 
curable type of hypertension with an estimated prevalence 
of 3-5% in hypertensive patients.1,2 RVH develops from 
the activation of the renin-angiotensin system due to renal 
arterial stenosis (RAS)3 and subsequent vasoconstriction and 
retention of sodium and water. 
RAS can be detected by arteriography and by other 
noninvasive imaging methods, such as magnetic resonance 
angiography (MRA), computed tomography angiography 
(CTA), and duplex ultrasound.4 The detection of stenosis 
alone does not guarantee the presence of RVH and may 
not be sufficient for defining a particular prognosis and 
treatment.
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Despite marked technical advances in the endovascular 
treatment of renal artery occlusive disease, the selection 
of patients who would benefit from surgical bypass or 
endovascular therapy remains controversial.5 Clinical 
improvement after vascular intervention is considered 
diagnostic for RVH, thereby reinforcing the finding 
that currently available non-invasive techniques are not 
sufficiently sensitive and specific. Therefore, there is 
an increasing interest in developing tests to evaluate the 
functional consequences of RAS to identify patients who 
may benefit from dilation procedures.6 
Captopril renal scintigraphy is used for the diagnosis of 
RVH7-9 and is a predictor of blood pressure reduction after 
surgery or angioplasty. Administration of an angiotensin 
converting enzyme (ACE) inhibitor leads to a decrease 
in glomerular filtration pressure, a prolonged transit time 
of tubular agents (99mTc-MAG3 or EC) and decreased 
uptake of glomerular agents (99mTc-DTPA). Captopril renal 
scintigraphy analysis is based on characterization of renal 
function deterioration when compared to a baseline study, 
as a decreased GFR is indirectly reflected in time-activity 
curves. 
51Cr-EDTA clearance provides an accurate and objective 
measurement of the GFR,10 and it can be used to quantify 
renal function deterioration induced by ACE inhibitors. A 
simplified method for direct measurement of baseline and 
post-captopril GFR using 51Cr-EDTA could add valuable 
information to the investigation of hypertensive patients 
with RAS, although scintigraphy would still be needed to 
assess differential renal function. Assuming that hypertensive 
patients with RAS have a higher probability of developing 
RVH than patients without RAS, we hypothesized that 
an effective test would show a greater decrease in GFR 
measurements in the first group of patients.
OBJECTIVES
The purpose of this study was to create a one-day 
protocol to measure baseline and post-captopril GFR with 
51Cr-EDTA. 
METHODS 
Patients 
From March 2007 to April 2009, 41 consecutive 
patients with poorly controlled severe hypertension were 
prospectively included in the study. Patients were recruited 
from either the Clinical Hospital Nephrology Department 
or from the Heart Hospital Hypertension Clinic, both of 
which are tertiary hospitals. Patients with chronic renal 
insufficiency (those undergoing dialysis or with a Cockcroft-
Gault estimated renal function below 15/ml/min) and women 
who were pregnant or lactating were excluded.
All patients had undergone a radiological investigation of 
RAS within a month prior to their inclusion in the study. The 
patients were divided into two groups: hypertensive patients 
with RAS and hypertensive patients without RAS. 
Clinical data recorded for all patients included: age, 
sex, time of hypertension onset, blood pressure (BP) level, 
antihypertensive drugs taken at the time of the study, 
other atherosclerotic risk factors (dyslipidemia, diabetes, 
smoking), and previous history of myocardial infarction (MI) 
or cerebral ischemia (CI).
The study was approved by the Hospital Ethics 
Committee, and all patients signed informed consent forms.
Procedures
Baseline and post-captopril GFR
Patients were instructed to stop taking antihypertensive 
drugs (including ACE inhibitors) for three to five days before 
the study. A single dose of 3.7 MBq (100 μCi) of 51Cr-EDTA, 
in a volume of one ml, was injected into an antecubital vein. 
The exact injected dose was determined by weighing the 
syringe before and after the injection on a high precision 
analytic balance. Accurately timed, nine-ml blood samples 
were drawn from the opposite arm at two, four, six, and 
eight hours after the injection. Captopril (50 mg) was orally 
administered five hours after 51Cr-EDTA administration, with 
blood pressure monitoring conducted every fifteen minutes 
for one hour thereafter.
To measure radioisotope activity, the blood samples 
were centrifuged at 3600 rpm for 10 minutes, and three ml 
of plasma was measured in a well counter calibrated to the 
energy of chromium-51 (320 keV). Each sample, including 
a three-ml aliquot of a reference solution of 3.7 MBq (100 
μCi) 51Cr- EDTA diluted to 500 ml in saline, was counted 
for five minutes. 
The first two plasma samples (two and four hours) were 
used to calculate the pre-captopril GFR, and the last two 
samples (six and eight hours) were used to calculate the 
post-captopril GFR. Plasma clearance rates were calculated 
by the slope-intercept method using a single-compartment 
model. Brochner-Mortensen’s method was used to correct 
the systematic error of the slope-intercept technique. The 
plasma clearance of 51Cr-EDTA was corrected for a 1.73 m² 
body surface.
Evaluation of individual renal function
An initial dose of 18.5 MBq (0.5 mCi) of 99mTc-DMSA 
was simultaneously injected with 51Cr-EDTA. After two 
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hours, anterior and posterior abdominal images were 
obtained for two minutes using a dual-headed gamma 
camera (ECam - Siemens; Hoffman Estates, Illinois, USA). 
A second dose of 167 MBq (4.5 mCi) of 99mTc-DMSA was 
injected one hour after captopril administration, and a second 
set of images was acquired at two hours post-administration. 
Differential renal function was semi-quantitatively estimated 
in both the baseline and the post-captopril studies by 
determining the geometric means of the anterior and 
posterior counts in the right and left kidney regions of 
interest (Figure 1).
Follow-up of patients
The group of patients with RAS were followed up to 
663 days after their inclusion in the study. BP level and 
antihypertensive drug classes in use six months after the 
initial evaluation were used to classify patients as either 
responders or non-responders to the therapy according 
to the Guidelines for the Reporting of Renal Artery 
Revascularization in Clinical Trials.11 Improvement in the 
control of hypertension was defined by a diastolic pressure 
lower than 90 mmHg and/or a systolic BP lower than 140 
mmHg upon use of the same or a less complex scheme of 
therapy (lower number of antihypertensive drug classes or 
dosages) or by a reduction in diastolic blood pressure of at 
least 15 mmHg.
Data analysis
Patient demographics were recorded, and the GFRs 
before and after captopril administration were compared. 
The mean, standard deviation, minimum and maximum 
values were determined for quantitative variables. Absolute 
and relative frequencies of qualitative variables were also 
calculated. The Student’s t test (unpaired) was employed to 
compare the quantitative variables, and categorical variables 
were compared by means of Fisher’s exact test. A p-value < 
0.05 was considered significant.
RESULTS
The group of patients with RAS included 21 patients 
(12 male, nine female). RAS was confirmed by either 
arteriography or MRA (in 18 and 3 cases, respectively). The 
mean±SD age was 62.1±9.1 years (range 42-78), and the time 
of hypertension onset was 16.2±12.0 years. Patients presented 
with a mean±SD systolic blood pressure of 161±23 mmHg 
and a mean±SD diastolic BP of 91±14 mmHg. The mean 
number (±SD) of antihypertensive drugs in use was 3.9 ±1.4. 
The group of patients without RAS included 20 patients 
(11 male, nine female). A non-stenotic renal artery was 
confirmed by arteriography in 16 cases and MRA and CTA in 
the remaining four cases. The mean±SD age was 53.1±10.3 
years (range 37–77) and the time of hypertension onset was 
12.7±9.4 years. The group of patients without RAS presented 
with a mean±SD systolic blood pressure of 167±23 mmHg 
and a mean±SD diastolic BP of 98±14 mmHg. The mean 
number (±SD) of antihypertensive drugs in use was 4.6±0.9. 
The group of patients with RAS were significantly older 
than those without RAS (p-value 0.005), with no statistically 
significant difference in the time of hypertension onset (p=0.3), 
systolic blood pressure (p=0.44), diastolic blood pressure 
(p=0.13), or number of antihypertensive drugs in use (p=0.08). 
There were no significant differences between groups regarding 
the prevalence of other atherosclerotic risk factors (diabetes 
and dyslipidemia) or of previous ischemic lesions (MI or CI) 
(p>0.1). Clinical and laboratory characteristics of patients with 
and without RAS are summarized in Table 1. 
Baseline and post-captopril GFR
The mean baseline GFR was 48.6±21.8 ml/kg/1.73 m2 in 
the group of patients with RAS, which was significantly lower 
than the GFR of 65.1±28.7 ml/kg/1.73 m2 in the group without 
RAS (p=0.04). Captopril induced a significant reduction of 
GFR in the group of patients with RAS (to 32.6±14.8 ml/
kg/1.73 m2, p=0.001) and a non-significant change in the 
group without RAS (to 62.2±23.6 ml/kg/1.73 m2, p=0.68). 
The percentage decrease in GFR was also greater in the group 
of patients with RAS than in the group without RAS (33% and 
4.5%, respectively, p=0.007). Baseline and post-captopril GFR 
results are summarized in Figure 2.
Evaluation of individual renal function
Differential renal function, estimated through pre- and 
post-captopril 99mTc-DMSA scintigraphies, was multiplied 
Figure 1 - General sequence of the protocol, including radiopharmaceutical 
administration and sample intervals. 
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of antihypertensive therapy was the therapeutic choice in 
eleven cases (eight males, 62.8±6 years), and interventional 
procedures (angioplasty in nine cases, nephrectomy in 
one) were adopted in the other ten patients (four males, 
61.4±11 years). No significant difference was found 
between those patients receiving drugs or submitted to 
angioplasty regarding age, time of onset of hypertension, 
number of antihypertensive drugs in use, or systolic blood 
pressure (171±22 vs. 153±20 mmHg, p=0.07), but the mean 
diastolic blood pressure was higher in patients submitted to 
angioplasty (97±12 vs. 85±14 mmHg, p=0.04). 
After a mean follow-up of 379 days (range of 206-
663 days), 15 patients had a good clinical response, as 
previously defined. Seven responders had been treated 
clinically (7/11=63% response rate) and eight had undergone 
interventions (8/10=80% response rate), with no significant 
difference between treatment strategies (p=0.36). There 
was a non-significant tendency towards a better response in 
patients with a higher baseline GFR (responders 53.7±22 ml/
min vs. non-responders 36.0±14 ml/min, p=0.09); however, 
no differences in the absolute or percentage decrease in GFR 
after captopril administration were observed. Considering 
only those 10 patients who received interventional therapy 
for RAS, no significant difference between responders and 
non-responders in either the baseline GFR or baseline/post-
captopril ratio was observed (p=0.83).
DISCUSSION
Use of clinical improvement after vascular intervention 
as a criterion for diagnosing RVH reinforces that currently 
available techniques are not sufficiently accurate for this 
diagnosis. Captopril renal scintigraphy is a predictor of 
blood pressure reduction after surgery or angioplasty, 7-9 but 
it may be hampered by dehydration, hydronephrosis, or other 
factors that affect the indirect analysis of renogram curves. 
A method capable of directly detecting captopril-induced 
changes in GFR, such as the one presented here, may help 
to select patients who may benefit from dilation procedures. 
This study showed that a one-day protocol with 
sequential measurements of 51Cr-EDTA clearance could 
be used to identify captopril-induced changes in GFR. 
Captopril induced a significantly greater decrease in the 
GFR of patients with confirmed RAS than in a control 
group of hypertensive patients without RAS. An exacerbated 
response to the inhibition of the renin-angiotensin system 
is a plausible explanation for this finding, although other 
variables, such as a lower baseline GFR, could have 
influenced the response. 
The one-day protocol described in this study is practical 
for clinical use and avoids the interference of factors such 
Table 1 - Clinical and laboratorial characteristics of patients 
in Groups RAS and no-RAS.
CLINICAL 
CHARACTERISTICS
Group RAS 
(n=21)
Group no-RAS 
(n=20)
Age 62.1±9.1 years 53.1±10.3 years
time of onset of hypertension 16.2±12.0 years 12.7±9.4 years
Systolic Blood Pressure 161±23  mmHg 167±23  mmHg
Diastolic Blood Pressure 91±14  mmHg 98±14  mmHg
Number of medications in use 3.9 ±1.4 4.6±0.9
Diabetes 9 (42.8%) 8 (40%)
Dyslipidemia 20 (95%) 18 (90%)
Smoking   (current) 4 (19%) 6 (30%)
Smoking  (previous) 12 (57%) 5 (25%)
Myocardial infarction 5 (23.8%) 6 (30%)
Cerebral ischemia 2 (9.5%) 5 (25%)
LABORATORY TEST  
RESULTS  
Creatinine (mg/dl) 1.6 ± 0.7 1.4 ±0.8
Urea (mg/dl) 58.0 ±28.1 43.8 ±21.6
Cholesterol (mg/dl) 188.8 ±48.8 205.8 ±42.6
Triglycerides (mg/dl) 180.6 ±145.1 154.9 ±83.4
Blood glucose (mg/dl) 110.0 ±29.3 142.4 ±70.5
Figure 2 - GFR before and after captopril administration in groups RAS and 
no-RAS. Group RAS exhibited a lower GFR at baseline and a significantly 
greater drop in the GFR after captorpril administration.
by the baseline and post-captopril GFR. The resultant 
function of each kidney was compared, considering 25 
stenotic and 17 non-stenotic units. Stenotic kidneys had a 
lower baseline GFR than non-stenotic kidneys (18.4 ml/min 
vs. 32.8 ml/min; p=0.01), as well as a lower post-captopril 
GFR (p=0.04); however, a significant difference in the 
baseline/post-captopril ratio was not observed (p=0.27).
Follow-up of patients with RAS
Therapy strategies were determined after completion of 
clinical and radiological investigations, and the decision to 
treat RAS patients with angioplasty was mainly based on 
the arteriographic characteristics of the lesion. Optimization 
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as patient preparation (including hydration status and 
suspension of antihypertensive drugs). On the other hand, the 
comparison of early (two to four-hour) and delayed (six to 
eight-hour) samples can result in a systematic error of GFR 
determination, which could be avoided if baseline and post-
captopril studies are performed with different injections on 
different days with sample collection performed at exactly 
the same intervals. Importantly, a systematic error does not 
explain the observed difference between groups of patients 
with and without RAS. The doses of captopril used in renal 
scintigraphy vary from 25 to 50 mg, leading to a peak 
plasma level at 40 to 60 minutes after its oral administration. 
We explored a period during maximum activity of the drug 
by using a 50 mg captopril dose and collecting plasma 
samples at six and eight hours (one and three hours after 
captopril administration).
An important limitation of 51Cr-EDTA clearance is 
that an in vitro technique does not permit determination of 
individual renal function. The global GFR of both kidneys is 
measured, and a decrease in filtration pressure of a stenotic 
kidney can be partially compensated for by an increased flow 
in the contralateral kidney. An experimental study confirmed 
that a captopril-induced decrease in inulin clearance (31%) 
occurs in a kidney with RAS, with no significant effect in the 
contralateral non-RAS kidney.12
Renal uptake of 99mTc-DMSA is strongly reduced 
after use of an ACE inhibitor in the presence of RVH.13 
Although DMSA is well known as a tubular agent, the 
tracer is partially filtered in the glomerulus and is reabsorbed 
by tubular cells, which explains the observed effect of 
captopril.14 In our study, post-captopril 99mTc-DMSA 
scintigraphy showed no significant variation in differential 
function as compared to the baseline study, even in patients 
with RAS and with significant decreases in the global GFR. 
DMSA uptake mechanisms are not completely understood, 
and a proportion of 35% GFR to 65% direct tubular uptake 
has been proposed by some authors.14 DMSA uptake may 
be only partially or not influenced by a decrease in GFR 
if reabsorption of filtered radiopharmaceuticals is not the 
dominant mechanism in chronically ischemic or poorly 
functioning kidneys. 
The lack of a direct comparison to captopril renography 
is the main limitation of this study because the functional 
significance of detected RAS is not clear. When the present 
study was designed, we believed that the clinical response to 
angioplasty would be the final criterion for RVH diagnosis. 
DTPA renal scintigraphy was performed in a non-systematic 
manner only when requested by the nephrologists. 
Captopril renography results may be influenced by different 
interpretation criteria15 and are usually less accurate in 
azotemic patients. When performed in patients with ischemic 
nephropathy or a poorly functioning kidney, as many as 
50% of the studies suggest an indeterminate probability of 
RVH.16,17 Absolute GFR measurement increases renogram 
sensitivity, and the combined analysis of renogram and GFR 
resulted in a specificity of 100% for exclusion of RAS in a 
prospective study of thirty hypertensive patients.18 
Plasma clearance of 51Cr-EDTA can be used to estimate 
GFR with high accuracy, and it is one of the best available 
indices of renal function, even for patients with a GFR as 
low as 15 ml/min.19 Quantitative determination of baseline 
and post-captopril GFR with EDTA could reduce the 
number of indeterminate results even in those patients 
with poor renal function.9 However, evaluation of atrophic/
hypo-functioning kidneys may be limited by the precision 
of measurements (improved with in vitro 51Cr-EDTA 
clearance) and by the coexistence of different vascular and 
fluid retention mechanisms in the genesis of hypertension.
Although the worsening of renal function following 
captopril administration is taken as an indicator of RVH, 
baseline/post captopril changes in GFR ratios did not 
allow for discrimination of responders to revascularization 
procedures from non-responders, limiting the clinical 
implication of this study.
The small number of patients and non-randomization 
of therapeutic procedures do not allow for a definitive 
conclusion to be drawn regarding the prognostic significance 
of the method. 
CONCLUSION
In conclusion, the baseline and post-captopril GFR can 
be quantitatively measured by 51Cr-EDTA clearance in a 
one-day procedure, thereby allowing for avoidance of any 
variation in preparation or other clinical conditions. 
Captopril induces a significantly greater drop in the GFR 
of hypertensive patients with RAS than in those without 
RAS, although this decrease was not related to a clinical 
response after intervention in this limited number of cases.
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